Myostatin / Activin Antagonism • Skeletal Muscle Biology • Gene-Therapy Research
Follistatin-344 occupies one of the most fascinating—and frequently misunderstood—areas of modern muscle biology.
Its relationship to myostatin inhibition, activin signaling, skeletal-muscle growth, reproductive endocrinology, and experimental gene therapy has generated substantial scientific interest alongside increasingly ambitious claims in the peptide marketplace.
But there is an important problem:
Not everything described as “Follistatin-344 evidence” studied the same intervention.
The FIME Follistatin-344 Peptide Intelligence Monograph traces the science from endogenous follistatin physiology through experimental muscle-growth research and human FS344 gene-therapy studies, while examining how—and whether—those findings translate to commercially marketed FST-344 products.
Follistatin has real biology, compelling preclinical research, and legitimate human translational investigation.
But how much of that evidence actually applies to the products now marketed as Follistatin-344?
That is where this monograph begins.
Version 1.0 Final
Published by the Founder’s Institute of Medicine & Education
For professional education and scientific review. Not individualized medical advice, prescribing guidance, bodybuilding or athletic-performance guidance, or a treatment protocol.
This publication is provided solely for educational and informational purposes. It does not constitute medical advice, diagnosis, prescribing guidance, or a recommendation for individual treatment. It is not intended to replace evaluation, consultation, or treatment by a qualified healthcare professional. Treatment decisions must be based on the individual patient's circumstances and made in consultation with an appropriately licesnsed healthcare professional.